The NKCE Solution Landscape
Six complementary solution areas organize the evaluation framework.
On smaller screens, scroll within the table to view all columns.
| Module | Solution Area | Approach |
|---|
| 01 | NK Cell Sorting & Processing | Establish a stable NK effector cell population with controlled donor factors |
| 02 | Subset & Target Phenotyping | Confirm NK subsets (CD56bright/dim, CD16) and target antigen expression (ABC quantification) |
| 03 | Functional Assays | A. NK cell activation profiling |
| B. Target-dependent cytotoxicity |
| C. Effector function & degranulation |
| D. Cytokine release assessment |
| E. Functional durability & exhaustion |
| F. On-target off-tumor toxicity evaluation |
| 04 | Reference System | Positive/negative controls and reference molecule (AFM13) |
| 05 | Candidate Integration | Multi-dimensional data integration into a candidate molecule profile |
| 06 | Pharmacokinetics | In vivo exposure, clearance and half-life evaluation |
Overview: Key Drivers of NKCE Activity
NK cell engagers (NKCEs) bind a tumor-associated target antigen and an activating receptor on the NK cell surface simultaneously — most commonly CD16A/FcγRIIIA, and also NKp46, NKG2D or NKp30 — drawing NK cells into close proximity with tumor cells, rebuilding the immune synapse, and driving NK cell activation, degranulation and target cell killing. Unlike T cells, NK cells are innate immune effectors: their killing does not require prior antigen sensitization, is not HLA-restricted, and allogeneic use does not cause graft-versus-host disease (GVHD); in theory, the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) is lower than with TCEs[6][10]. However, NK cells account for only a small fraction of peripheral blood mononuclear cells (PBMCs) (approximately 5–15%) and show wide donor-to-donor variability, which places different demands on assay system design than TCE development.
The ultimate pharmacological performance of an NKCE is likewise governed by several factors acting together. The three most critical variables are the affinity of the two binding arms, the structural format of the molecule, and the expression level of the target antigen.
Affinity
The affinity of the CD16A (or other NK activating receptor) binding arm determines the strength and threshold of NK cell activation. Unlike CD3, NK cells themselves express CD16A — excessively high affinity or an inappropriate valency design can trigger NK-to-NK “fratricide” and accelerate ADAM17-mediated CD16 cleavage and shedding after activation, shortening the effective window of action[3][4]. The target antigen arm generally requires higher affinity to ensure recognition of low-density antigens. An ideal NKCE must find a balance window between “sufficient activation” and “avoiding fratricide / CD16 shedding”.
Molecular Format
The presence or absence of an Fc domain, binding valency (BiKE-type tandem scFv, tetravalent TandAb, IgG-like bispecific, etc.) and geometric configuration determine the molecule's half-life, whether it competes with endogenous IgG for CD16A binding, and the efficiency of immune synapse formation. For example, Fc-free BiKE formats are small and short-lived but penetrate tumors well; Fc-containing IgG-like formats must have their Fc fully silenced to avoid non-specific activation through FcγR crosslinking and occupancy interference with CD16A binding.
Target Antigen Expression
Antigen density, homogeneity and distribution in normal tissues (normal cells that NK cells can respond to) directly affect NKCE killing activity and the risk of on-target/off-tumor toxicity. Antigen density that is too low or heterogeneous expression leads to reduced efficacy or relapse.
Six Questions for NKCE Evaluation
Q1 · ActivationAre NK cells activated to an appropriate degree?
Whether the activation strength is sufficient to support degranulation and killing — not simply “the higher the activation, the better”. Excessive activation brings CD16 shedding, NK functional decline and fratricide risk.
Q2 · CytotoxicityCan target cells be effectively killed?
Whether the candidate has sufficient target cell killing activity and can produce a detectable, quantifiable killing effect in functional assays.
Q3 · Target DependenceIs the activity truly target antigen-dependent?
Whether the killing effect is a target-dependent mechanism mediated by the NKCE, or non-specific background in the assay system (including fratricide of NK cells by free NKCE). This must be determined by comparing target antigen-positive and antigen-negative cells.
Q4 · CytokinesIs excessive cytokine release involved?
Whether the release of NK-derived cytokines (IFN-γ, TNF-α, GM-CSF, etc.) is controllable, and whether amplification signals such as IL-6 remain within a safe range in monocyte-containing PBMC or whole blood systems.
Q5 · DurabilityCan function be maintained after long-term stimulation?
Whether NK cells show exhaustion-related phenotypes (upregulation of NKG2A, TIM-3, TIGIT, etc.) under repeated stimulation, and how durable function is with cytokine support (e.g., IL-15).
Q6 · Candidate IntegrationWhich candidate is most worth advancing?
Integrating all dimensions into a consolidated NKCE candidate profile to identify the lead candidate most worth advancing.
Reference System & Benchmark Molecule
AFM13 (CD30 × CD16A)
The solution described here uses the first NKCE to enter clinical development — AFM13 (CD30×CD16A) — as its cross-cutting methodological reference. AFM13 is a tetravalent bispecific TandAb antibody construct developed by Affimed: Fc-free, bivalent for both CD16A and CD30, it efficiently recruits NK cells to lyse CD30+ tumor cells[1]. In a phase 1 dose-escalation study (relapsed/refractory Hodgkin lymphoma, 28 patients, 0.01–7 mg/kg), AFM13 was generally well tolerated (maximum tolerated dose not reached), with a serum half-life of up to approximately 19 hours, and significant NK cell activation together with a decrease in peripheral soluble CD30 (sCD30) were observed[1]. In the modules above, “AFM13 reference data” provides the experimental condition framework as a basis for system qualification and candidate comparison; for any value marked [to be verified], please refer to the primary literature or internal replicate data.
